Compare · ABT vs VIVO
ABT vs VIVO
Side-by-side comparison of Abbott Laboratories (ABT) and VivoPower PLC (VIVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ABT operates in Health Care, while VIVO operates in Utilities - the two are in different parts of the market.
- ABT is the larger of the two at $187.95B, about 2743.2x VIVO ($68.5M).
- ABT has been more active in the news (8 items in the past 4 weeks vs 6 for VIVO).
- ABT has more recent analyst coverage (25 ratings vs 3 for VIVO).
- Company
- Abbott Laboratories
- VivoPower PLC
- Price
- -
- -
- Market cap
- $187.95B
- $68.5M
- 1M return
- +3.63%
- -
- 1Y return
- -16.55%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Power Generation
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 3
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
VivoPower PLC
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Latest ABT
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Latest VIVO
- VivoPower’s Tembo Launches KOVA, its 4WD All-Electric Dual-Motor Platform and Utility Pickup Truck
- VivoPower Confirms Strategic Update and Results Conference Call Moved to November 16, 2026
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Reports Unaudited First Quarter Fiscal Year 2027 Results with Revenue of US$6.8 Million, Net Profit of US$0.6 Million and Positive Operating Cash Flow of US$2.1 Million
- VivoPower Reports FY2026 Results Including a Partial-Period Contribution from Mo i Rana Data Center
- SEC Form 20-F filed by VivoPower PLC
- VivoPower Signs Definitive Heads of Agreement with Open Innovation AI to Develop Secure Sovereign AI Data Centers Across the Nordics, Mainland Europe, the GCC and selective countries in Asia
- VivoPower Mobilizes Construction of 40MW AI Data Center Conversion in Mo i Rana, Norway
- SEC Form 6-K filed by VivoPower PLC
- SEC Form 6-K filed by VivoPower PLC